Clinical trialNATerminated
Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer
Monocentric, Prospective Study Assessing the Feasibility to Use Resting Energy Expenditure by Indirect Calorimetry as Prognostic Marker of Tumoral Response to 1st Line Chemotherapy in Patients Suffering From Metastatic Pancreatic Cancer
- Outcome
- Stopped earlyProtocol is not adapted to cancer pancreas disease as progression is very fast and patients stopped the study before 1st study assessment (Other)
- Phase
- NA
- Status
- Terminated
- Study type
- Interventional
- Start
- 10 July 2017
- Expected end
- 10 July 2019
- Enrollment
- 8 participants
- Sites
- 1
- Primary outcomes
- Resting energetic expenditure measurement by indirect calorimetry
- Sponsor
- Other
- Results posted
- No
- Last update
- 27 January 2020
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to determine whether evolution of resting energetic expenditure is a predictive marker of tumoral response for patients suffering from metastatic pancreatic cancer and treated with 1st line of chemotherapy.